Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its fourth quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.270-1.300 for the period. The company issued revenue guidance of $1.2 billion-$1.2 billion. Illumina also updated its FY 2025 guidance to 4.760-4.790 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. JPMorgan Chase & Co. lifted their price target on Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, January 3rd. TD Cowen raised their target price on Illumina from $115.00 to $140.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Finally, Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Illumina presently has an average rating of “Hold” and a consensus price target of $122.56.

Illumina Price Performance

NASDAQ ILMN traded up $0.71 during trading on Tuesday, reaching $146.26. The company’s stock had a trading volume of 857,805 shares, compared to its average volume of 1,752,380. The stock has a market capitalization of $22.35 billion, a PE ratio of 32.79, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm has a fifty day moving average of $130.52 and a 200 day moving average of $110.24. Illumina has a one year low of $68.70 and a one year high of $153.06.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company posted $1.14 EPS. The company’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ILMN. Parallel Advisors LLC boosted its position in Illumina by 4.7% during the 3rd quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock valued at $269,000 after buying an additional 128 shares during the period. Zacks Investment Management boosted its holdings in shares of Illumina by 0.6% during the third quarter. Zacks Investment Management now owns 24,655 shares of the life sciences company’s stock worth $2,342,000 after purchasing an additional 143 shares during the period. Prelude Capital Management LLC boosted its holdings in shares of Illumina by 11.2% during the third quarter. Prelude Capital Management LLC now owns 2,770 shares of the life sciences company’s stock worth $263,000 after purchasing an additional 279 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of Illumina by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 49,420 shares of the life sciences company’s stock worth $4,693,000 after purchasing an additional 307 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Illumina by 12.4% during the 3rd quarter. NewEdge Advisors LLC now owns 3,073 shares of the life sciences company’s stock valued at $292,000 after purchasing an additional 338 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.